C
Cyrus R. Mehta
Researcher at Cytel
Publications - 141
Citations - 11676
Cyrus R. Mehta is an academic researcher from Cytel. The author has contributed to research in topics: Sample size determination & Contingency table. The author has an hindex of 41, co-authored 138 publications receiving 10711 citations. Previous affiliations of Cyrus R. Mehta include Dana Corporation & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White,Christopher P. Cannon,Simon Heller,Steven E. Nissen,Richard M. Bergenstal,George L. Bakris,Alfonso Perez,Penny R. Fleck,Cyrus R. Mehta,Stuart Kupfer,Craig A. Wilson,William C. Cushman,Faiez Zannad +12 more
TL;DR: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo.
Journal ArticleDOI
A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables
Cyrus R. Mehta,Nitin R. Patel +1 more
TL;DR: In this paper, the problem of finding all paths through a directed acyclic network that equal or exceed a fixed length is transformed into one of identifying all paths in a directed ACYCLIC network.
Journal Article
A network algorithm for performing Fisher's exact test in rxc contingency tables
TL;DR: A novel technique that considerably extends the bounds of computational feasibility of the exact test is proposed here and is transformed into one of identifying all paths through a directed acyclic network that equal or exceed a fixed length.
Journal ArticleDOI
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad,Christopher P. Cannon,William C. Cushman,George L. Bakris,Venu Menon,Alfonso Perez,Penny R. Fleck,Cyrus R. Mehta,Stuart Kupfer,Craig A. Wilson,Hung Lam,William B. White +11 more
TL;DR: In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes and results did not differ by baseline BNP concentration.
Journal ArticleDOI
A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma
Christine Léauté-Labrèze,Peter H. Hoeger,Juliette Mazereeuw-Hautier,Laurent Guibaud,Eulalia Baselga,Gintas Posiunas,Roderic J Phillips,Héctor Cáceres,Juan Carlos López Gutiérrez,Rosalia Ballona,Sheila Fallon Friedlander,Julie Powell,Danuta Perek,Brandie J. Metz,Sébastien Barbarot,Annabel Maruani,Zsuzsanna Szalai,Alfons Krol,Olivia Boccara,Regina Foelster-Holst,María Isabel Febrer Bosch,John C Su,Hana Buckova,Antonio Torrelo,Frédéric Cambazard,Rainer Grantzow,Orli Wargon,Dariusz Wyrzykowski,Jochen Roessler,Jose Bernabeu-Wittel,Adriana M Valencia,Przemysław Przewratil,Sharon A. Glick,Elena Pope,Nicholas Birchall,Latanya Benjamin,Anthony J. Mancini,Pierre Vabres,Pierre Souteyrand,Ilona J. Frieden,Charles I Berul,Cyrus R. Mehta,Sorilla Prey,Franck Boralevi,Caroline C. Morgan,Stephane Heritier,Alain Delarue,Jean-Jacques Voisard +47 more
TL;DR: This trial showed that propranolol was effective at a dose of 3 mg per kilogram per day for 6 months in the treatment of infantile hemangioma.